

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. BOX 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/905,189		07/13/2001	Guang-Jong Jason Wei	163.1438US01	3059	
23552	7590	06/10/2004		EXAMINER		
MERCHAN		OULD PC		PAK, JO	OHN D	
P.O. BOX 29 MINNEAPO		55402-0903		ART UNIT	PAPER NUMBER	
	ŕ			1616		
				DATE MAILED: 06/10/2004	FD: 06/10/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		09/905,189	WEI ET AL.				
Office Action	Summary	Examiner	Art Unit				
		JOHN D PAK	1616				
	E of this communication app	pears on the cover sheet with the c	orrespondence address				
THE MAILING DATE OF - Extensions of time may be availa after SIX (6) MONTHS from the r - If the period for reply specified at - If NO period for reply is specified - Failure to reply within the set or e	THIS COMMUNICATION. ble under the provisions of 37 CFR 1.1 nailing date of this communication. sove is less than thirty (30) days, a replabove, the maximum statutory period xtended period for reply will, by statute ater than three months after the mailin	Y IS SET TO EXPIRE 3 MONTH(136(a). In no event, however, may a reply be tirr by within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from a, cause the application to become ABANDONE by date of this communication, even if timely filed	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
_		Tahanan 2004 and 04 And 2004					
1)⊠ Responsive to com 2a)☐ This action is FINA	· · · · <u>—</u>	ebruary 2004 and 01 April 2004.					
3) Since this application	This action is FINAL . 2b) ☑ This action is non-final. Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4a) Of the above classified the state of th	aim(s) is/are withdra are allowed. <u>15-20,23-33 and 35-47</u> is/a	are rejected.					
Application Papers							
10) The drawing(s) filed Applicant may not red Replacement drawing	quest that any objection to the sheet(s) including the correc	er. cepted or b) objected to by the B drawing(s) be held in abeyance. See tion is required if the drawing(s) is obj xaminer. Note the attached Office	e 37 CFR 1.85(a). lected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 1	19						
a) All b) Some 1. Certified cop 2. Certified cop 3. Copies of the application fr	t c) None of: ies of the priority document ies of the priority document e certified copies of the prior om the International Burea	ts have been received in Applicati ority documents have been receive	on No ed in this National Stage				
Attachment(s) 1) Notice of References Cited (P2) Notice of Draftsperson's Pate		4) ☐ Interview Summary Paper No(s)/Mail Da					
	nt Drawing Review (PTO-948) Hent(s) (PTO-1449 or PTO/SB/08)		atent Application (PTO-152)				

Office Action Summary

Art Unit: 1616

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/23/2004 has been entered.

Claims 1-9, 11-12, 15-20, 23-33, 35-47 are pending in this application.

In the Office action of 9/23/2002, a requirement was made under 35 USC 121 to elect a single disclosed species comprising mono or diester dicarboxylates such as monomethyl malonate. That requirement is maintained and repeated herein. In applicant's reply of 1/15/2003, applicant elected with traverse sebacic acid esters and adipic acid esters. In the absence of contrary indication by applicant in this RCE application, the election carries over here. The pending claims will therefore continue to be examined to the extent that they read on the elected subject matter of record, i.e. sebacic acid esters and adipic acid esters.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Art Unit: 1616

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-9, 11-12, 17-20, 23-31, 33, 35, 42-46 stand rejected under 35 USC 102(b) as being anticipated by Carr et al. for the reasons of record (see the Office action of 3/26/2003, pages 3-5; and Office action of 11/4/2003, pages 3-4) and for additional reasons given below.

Applicant's amendments and remarks of 2/23/2004 have been given due consideration, but they were deemed unpersuasive.

Applicants' arguments rely on the fact that all independent claims have been amended to recite a feature wherein the composition is "free of added strong inorganic acid" and/or the method requires "avoiding any addition of strong inorganic acid." However, a close reading of Carr et al. (WO 98/28267) shows explicit selection of an organic acid, thereby being free of added strong inorganic acid. In Examples 17-20 on page 18, Carr et al. selected MSA, i.e. methyl sulfonic acid, and p-TSA, i.e. p-toluenesulfonic acid, as the acid catalyst. Note, Examples 17-20 contain, inter alia, hydrogen peroxide and adipic acid (see p. 17, lines 15-16 ("DBE" contains adipic acid)). No strong inorganic acid was added, and hence, any and all strong inorganic acid was avoided.

Art Unit: 1616

Therefore, for the reasons of record and for the reasons further clarified herein, Carr et al. explicitly disclose the dicarboxylate ester compounds under examination here, in combination with hydrogen peroxide, free of added strong inorganic acid, wherein all additional claim-recited features are explicitly met for the reasons fully set forth in the previous Office actions. Specific examples are provided by Carr et al. wherein there is no added strong inorganic acid. That, taken with the reasons of record, is sufficient disclosure for anticipation. The holding and reasoning in In re
Sivaramakrishnan, 213 USPQ 441 (CCPA 1982), are applicable here, because explicit disclosure of a necessary species, organic acid (which by necessity means that inorganic acid is not selected, and thus is "free of added strong inorganic acid") satisfies the anticipation requirement for a disclosure. Id, at 442. The claims thereby remain rejected as being anticipated.

Claims 1-9, 11-12, 15-20, 23-33, 35-47 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Carr et al. in view of Hei, Chemical Abstracts 134:97683 and Richter et al. for the reasons of record (see the Office action of 3/26/2003, pages 6-7; and Office action of 11/4/2003, pages 4-7) and for additional reasons given below.

Applicant's amendments and remarks of 2/23/2004 have been given due consideration, but they were deemed unpersuasive.

Applicant's arguments about percentages and activity recited in the claims have already been fully responded to in the Office action of 11/4/2003, pages 4-6, which reasons are incorporated herein by reference.

Art Unit: 1616

Applicants' further arguments rely on the fact that all independent claims have been amended to recite a feature wherein the composition is "free of added strong inorganic acid" and/or the method requires "avoiding any addition of strong inorganic acid." However, a close reading of Carr et al. (WO 98/28267) shows explicit selection of an organic acid, thereby being free of added strong inorganic acid. In Examples 17-20 on page 18, Carr et al. selected MSA, i.e. methyl sulfonic acid, and p-TSA, i.e. p-toluenesulfonic acid, as the acid catalyst. Note, Examples 17-20 contain, inter alia, hydrogen peroxide and adipic acid (see p. 17, lines 15-16 ("DBE" contains adipic acid)). No strong inorganic acid was added, and hence, any and all strong inorganic acid was avoided.

Therefore, for the reasons of record and for the reasons further clarified herein, Carr et al. explicitly disclose the dicarboxylate ester compounds under examination here, in combination with hydrogen peroxide, free of added strong inorganic acid, wherein all additional claim-recited features are explicitly met and/or suggested for the reasons fully set forth in the previous Office actions. Specific examples are provided by Carr et al. wherein there is no added strong inorganic acid.

For these reasons and for the reasons of record, which are incorporate herein by reference, the claimed invention, as a whole, would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made. Carr et al. provide the expectation that their composition, which is directly readable on applicant's composition, would possess superior activity, as claimed (see the discussion of expected activity in the Office action of 11/4/2003, page 3, first full paragraph to page 7, second full

Art Unit: 1616

paragraph). One log reduction is not a demanding test, and such level of activity would have been expected for compositions that contain the quantity of hydrogen peroxide and peroxyacids present in the instant claims.

Consequently, all claims must be rejected again. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to JOHN PAK whose telephone number is (571)272-0620, effective February 3, 2004. The Examiner can normally be reached on Monday to Friday from 8 AM to 4:30 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's SPE. Thurman Page, can be reached on (571)272-0602, effective February 3, 2004.

The fax phone number for the organization where this application or proceeding is assigned is (703)872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571)272-1600.